The agreements involve firms representing 93% of the pending cases in the U.S. The firms are advising their clients to accept the settlement, which is expected to be finalized by mid-2025, according to an Oct. 9 news release from the company.
In addition to the settlement, GSK agreed to pay $70 million to resolve a qui tam complaint filed by testing laboratory Valisure, pending approval from the Justice Department.
While the settlements are not an admission of liability on the part of GSK, the drugmaker said the agreements are in its long-term interest, the release said.
A Chicago jury failed to reach a verdict Sept. 18 over claims that Zantac causes cancer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.